Varim MM, Le Pottier L, Youinou P, Saulep D, Mackay F, Pers JO: B-cell tolerance breakdown in Sjögren's syndrome: focus on BAFF. Autoimmun Rev. 2010, 9: 604-608. 10.1016/j.autrev.2010.05.006.
Article
Google Scholar
Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM: Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978, 89: 888-892.
Article
CAS
PubMed
Google Scholar
Baimpa E, Dahabreh U, Voulgarelis M, Moutsopoulos HM: Hematologic manifestations and predictors of lymphoma development in primary Sjögren's syndrome: clinical and pathophysiological aspects. Medicine. 2009, 88: 284-293. 10.1097/MD.0b013e3181b76ab5.
Article
PubMed
Google Scholar
Tapinos NI, Polihronis M, Tzioufas AG, Skopouli FN: Immunopathology of Sjögren's syndrome. Ann Med Interne (Paris). 1998, 149: 17-24.
CAS
Google Scholar
Mavragani CP, Crow MK: Activation of the type I interferon pathway in primary Sjogren's syndrome. J Autoimmun. 2010, 35: 225-231. 10.1016/j.jaut.2010.06.012.
Article
CAS
PubMed
Google Scholar
Mariette X, Gottenberg JE: Pathogenesis of Sjögren's syndrome and therapeutic consequences. Curr Opin Rheumatol. 2010, 22: 471-477. 10.1097/BOR.0b013e32833c36c5.
Article
CAS
PubMed
Google Scholar
Hansen A, Lipsky PE, Dörner T: Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol. 2005, 17: 558-565. 10.1097/01.bor.0000172801.56744.c3.
Article
CAS
PubMed
Google Scholar
Yoon KC, Jeong IY, Park YG, Yang SY: Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea. 2007, 26: 431-437. 10.1097/ICO.0b013e31803dcda2.
Article
PubMed
Google Scholar
Koski H, Janin A, Humphreys-Beher MG, Sorsa T, Malmström M, Konttinen YT: Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sjögren's syndrome. Clin Exp Rheumatol. 2001, 19: 131-137.
CAS
PubMed
Google Scholar
Baturone R, Soto MJ, Márquez M, Macías I, de Oca MM, Medina F, Chozas N, García-Pérez S, Girón-González JA: Health-related quality of life in patients with primary Sjögren's syndrome: relationship with serum levels of proinflammatory cytokines. Scand J Rheumatol. 2009, 38: 386-389. 10.1080/03009740902973821.
Article
CAS
PubMed
Google Scholar
Sisto M, D'Amore M, Caprio S, Mitolo V, Scagliusi P, Lisi S: Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of the salivary glands. Ann N Y Acad Sci. 2009, 1171: 407-414. 10.1111/j.1749-6632.2009.04688.x.
Article
PubMed
Google Scholar
Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T: Infliximab in patients with primary Sjögren's syndrome. Arthritis Rheum. 2001, 44: 2371-2375. 10.1002/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W.
Article
CAS
PubMed
Google Scholar
Steinfeld SD, Demols P, Appelboom T: Infliximab in primary Sjögren's syndrome. Arthritis Rheum. 2002, 46: 3301-3303. 10.1002/art.10674.
Article
CAS
PubMed
Google Scholar
Steinfeld SD, Appelboom T, Delporte C: Treatment with infliximab restores normal aquaporin 5 distribution in minor salivary glands of patients with Sjögren's syndrome. Arthritis Rheum. 2002, 46: 2249-2251. 10.1002/art.10440.
Article
PubMed
Google Scholar
Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puéchal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J: Inefficacy of Infliximab in primary Sjögren's syndrome. Arthritis Rheum. 2004, 50: 1270-1276. 10.1002/art.20146.
Article
CAS
PubMed
Google Scholar
Batten M, Fletcher C, Ng LG, Groom J, Wheway J, Laâbi Y, Xin X, Schneider P, Tschopp J, Mackay CR, Mackay F: TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol. 2004, 172: 812-822.
Article
CAS
PubMed
Google Scholar
Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Baum BJ, Pillemer SR: Etanercept in Sjögren's syndrome. Arthritis Rheum. 2004, 50: 2240-2245. 10.1002/art.20299.
Article
CAS
PubMed
Google Scholar
Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F: Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J Rheumatol. 2004, 31: 96-101.
CAS
PubMed
Google Scholar
Moutsopoulos NM, Katsifis GE, Angelov N, Leakan RA, Sankar V, Pillemer S, Wahl SM: Lack of efficacy of etanercept in Sjögren's syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis. 2008, 67: 1437-1443. 10.1136/ard.2007.077891.
Article
CAS
PubMed
Google Scholar
Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK: Augmented interferon-α pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum. 2007, 56: 3995-4004. 10.1002/art.23062.
Article
PubMed Central
CAS
PubMed
Google Scholar
Onishi S, Nagashima T, Kimura H, Matsuyama Y, Yoshio T, Minota S: Systemic lupus erythematosus and Sjögren's syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C. Lupus. 2010, 19: 753-755. 10.1177/0961203309353172.
Article
CAS
PubMed
Google Scholar
Zheng L, Zhang Z, Yu C, Tu L, Zhong L, Yang C: Association between IFN-alpha and primary Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009, 107: e12-e18. 10.1016/j.tripleo.2008.09.015.
Article
PubMed
Google Scholar
Båve U, Nordmark G, Lövgren T, Rönnelid J, Cajander S, Eloranta ML, Alm GV, Rönnblom L: Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. 2005, 52: 1185-1195. 10.1002/art.20998.
Article
PubMed
Google Scholar
Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, Labetoulle M, Ardizzone M, Sibilia J, Fournier C, Chiocchia G, Mariette X: Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci USA. 2006, 103: 2770-2775. 10.1073/pnas.0510837103.
Article
PubMed Central
CAS
PubMed
Google Scholar
Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA: Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol. 2008, 38: 2024-2033. 10.1002/eji.200738008.
Article
CAS
PubMed
Google Scholar
Lövgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Rönnblom L: Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. Arthritis Rheum. 2006, 54: 1917-1927. 10.1002/art.21893.
Article
PubMed
Google Scholar
Ittah M, Miceli-Richard C, Gottenberg JE, Lavie F, Lazure T, Ba N, Sellam J, Lepajolec C, Mariette X: B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res Ther. 2006, 8: R51-10.1186/ar1912.
Article
PubMed Central
PubMed
Google Scholar
Shiozawa S, Morimoto I, Tanaka Y, Shiozawa K: A preliminary study on the interferon-alpha treatment for xerostomia of Sjögren's syndrome. Br J Rheumatol. 1993, 32: 52-54. 10.1093/rheumatology/32.1.52.
Article
CAS
PubMed
Google Scholar
Ferraccioli GF, Salaffi F, De Vita S, Casatta L, Avellini C, Carotti M, Beltrami CA, Cervini C, Bartoli E: Interferon alpha-2 (IFNα2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol. 1996, 14: 367-371.
CAS
PubMed
Google Scholar
Shiozawa S, Tanaka Y, Shiozawa K: Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. J Interferon Cytokine Res. 1998, 18: 255-262. 10.1089/jir.1998.18.255.
Article
CAS
PubMed
Google Scholar
Ship JA, Fox PC, Michalek JE, Cummins MJ, Richards AB: Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res. 1999, 19: 943-951. 10.1089/107999099313497.
Article
CAS
PubMed
Google Scholar
Cummins MJ, Papas A, Kammer GM, Fox PC: Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum. 2003, 49: 585-593. 10.1002/art.11199.
Article
CAS
PubMed
Google Scholar
Smith JK, Siddiqui AA, Modica LA, Dykes R, Simmons C, Schmidt J, Krishnaswamy GA, Berk SL: Interferon-alpha upregulates gene expression of aquaporin-5 in human parotid glands. J Interferon Cytokine Res. 1999, 19: 929-935. 10.1089/107999099313479.
Article
CAS
PubMed
Google Scholar
Mariette X: Therapeutic potential for B-cell modulation in Sjögren's syndrome. Rheum Dis Clin North Am. 2008, 34: 1025-1033. 10.1016/j.rdc.2008.08.014.
Article
PubMed
Google Scholar
Pijpe J, van Imhoff GW, Spijkervet FKL, Roodenburg JLN, Wolbink GJ, Mansour K, Vissink A, Kallenberg CGM, Bootsma H: Rituximab treatment in patients with primary Sjögren's syndrome. Arthritis Rheum. 2005, 52: 2740-2750. 10.1002/art.21260.
Article
CAS
PubMed
Google Scholar
Meijer JM, Pijpe J, Vissink A, Kallenberg CGM, Bootsma H: Treatment of primary Sjögren's syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis. 2009, 68: 284-285. 10.1136/ard.2008.092601.
Article
CAS
PubMed
Google Scholar
Pijpe J, Meijer JM, Bootsma H, van der Wal JE, Spijkervet FKL, Kallenberg CGM, Vissink A, Ihrler S: Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum. 2009, 60: 3251-3256. 10.1002/art.24903.
Article
CAS
PubMed
Google Scholar
Devauchelle-Pensec V, Pennec Y, Morvan J, Pers J-O, Daridon C, Jousse-Joulin S, Roudaut A, Jamin C, Renaudineau Y, Quintin Roué I, Cochener B, Youinou P, Saraux A: Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007, 57: 310-317. 10.1002/art.22536.
Article
CAS
PubMed
Google Scholar
Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P: Reduction of fatigue in Sjögren's syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008, 67: 1541-1544. 10.1136/ard.2007.083865.
Article
CAS
PubMed
Google Scholar
Meijer JM, Meiners PM, Vissink A, Spijkervet FKL, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CGM, Bootsma H: Effectiveness of rituximab treatment in primary Sjögren's syndrome. A randomized double-blind, placebo-controlled trial. Arthritis Rheum. 2010, 62: 960-968. 10.1002/art.27314.
Article
CAS
PubMed
Google Scholar
Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X: Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007, 66: 700-703. 10.1136/ard.2006.060772.
Article
PubMed Central
CAS
PubMed
Google Scholar
Pers J-O, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, Hutin P, Renaudineau Y, Dueymes M, Loisel S, Berthou C, Saraux A, Youinou P: BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum. 2007, 56: 1464-1477. 10.1002/art.22603.
Article
PubMed
Google Scholar
Abdulahad WH, Meijer JM, Kroese FGM, Meiners PM, Vissink A, Spijkervet FKL, Kallenberg CGM, Bootsma H: B-cell reconstitution and T-helper-cell balance after rituximab treatment of active primary Sjögren's syndrome. Arthritis Rheum. 2011,
Google Scholar
Devauchelle-Pensec V, Cagnard N, Pers JO, Youinou P, Saraux A, Chiocchia G: Gene expression profile in the salivary gland of primary Sjögren syndrome patients, before and after treatment with Rituximab. Arthritis Rheum. 2010, 62: 2262-2271. 10.1002/art.27509.
Article
CAS
PubMed
Google Scholar
Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, Pradier O: Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006, 8: R129-10.1186/ar2018.
Article
PubMed Central
PubMed
Google Scholar
Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest. 2002, 109: 59-68.
Article
PubMed Central
CAS
PubMed
Google Scholar
Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R: The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis. 2003, 62: 168-171. 10.1136/ard.62.2.168.
Article
PubMed Central
CAS
PubMed
Google Scholar
Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X: Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. J Pathol. 2004, 202: 496-502. 10.1002/path.1533.
Article
CAS
PubMed
Google Scholar
Routsias JG, Tzioufas AG: Autoimmune response and target autoantigens in Sjogren's syndrome. Eur J Clin Invest. 2010, 40: 1026-1036. 10.1111/j.1365-2362.2010.02342.x.
Article
CAS
PubMed
Google Scholar
Pijpe J, Kalk WW, Bootsma H, Spijkervet FK, Kallenberg CG, Vissink A: Progression of salivary gland dysfunction in patients with Sjogren's syndrome. Ann Rheum Dis. 2007, 66: 107-112. 10.1136/ard.2006.052647.
Article
PubMed Central
CAS
PubMed
Google Scholar